Navigation Links
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/28/2009

J. Herzog, J. B. Vermorken, E. Pujade-Lauraine, J. Li, E. Bayever, J. Gomez, A. Yovine, B. J. Monk; Columbia University Medical Center, New York, NY; University Hospital Antwerp, Antwerp, Belgium; Hopital Hotel-Dieu, Paris, France; Johnson & Johnson PRD, USA, Raritan, NJ; PharmaMar SAU, Colmenar Viejo, Madrid, Spain; University of California Irvine Medical Center, Orange, CA

  • Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the OVA-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD (Abstract 5551)

General Poster Session, Sunday May 31, 2:00 pm to 6:00 pm, Level 2, West Hall C

Authors: A. Poveda, S. B. Kaye, R. T. McCormack, S. Wang, D. Ricci, E. Broderick, T. Parekh, C. Lebedinsky, J. C. Tecero, B. J. Monk; Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Research & Development, Raritan, NJ; PharmaMar SAU, Madrid, Spain; University of California Irvine Medical Center, Orange, CA

  • Early hemoglobin decline and survival prognosis in epoetin alfa studies (Abstract 9625)

General Poster Session, Monday June 1, 8:00 am to 12:00 pm, Level 2, West Hall C

Authors: J. A. Berlin, P. J. Bowers, S. Rao, S. Sun, K. Liu, D. H. Henry; Johnson & Johnson PRD, Titusville, NJ; Johnson & Johnson PRD, Raritan, NJ; Pennsylvania Onc Hem Assoc, Philadelphia, PA

  • Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) vers
    '/>"/>

SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. GeneNews provides Centocor access to its osteoarthritis program
7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
11. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
(Date:12/11/2009)... MA (12/11/2009) Boston College researchers have observed the ... first time and successfully harvested the elusive charges using ... solar power efficiency, the authors report in the current ... When light is captured in solar cells, it generates ... in order to snare these charges, the electrons must ...
(Date:12/11/2009)... 11 Algeta ASA (OSE: ALGETA), ... clinical center in the,US, the Tulane Cancer ... the phase III clinical study of Alpharadin ... prostate cancer,(CRPC) that has metastasized to the ... ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) study ...
(Date:12/11/2009)... Dec. 11 Gwathmey, Inc., a ... in cancer, staph aureus, and cardiovascular disease announces ... announced today that Rosalie Dunn, Ph.D., has joined ... has over 28 years of experience working with ... to joining Gwathmey, Dr. Dunn managed multimillion dollar ...
Breaking Biology Technology:miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2
... China Technology,Development Group Corporation (Nasdaq: CTDC; "the Company" ... products and solutions focusing on,solar energy business in ... ceremony to showcase the first SnO2 production line ... 2007., Accompanied by Mr. Alan Li, our ...
... 3 Neogen Corporation,(Nasdaq: NEOG ) announced today ... 2008, which ended Nov. 30, increased 34% from the ... net income in the,quarter rose to $0.22 per share, ... income of $3,254,000 set another quarterly,record for the 25-year-old ...
... a cancer therapeutics,company, announced today the appointment of ... of Directors. Mr. Clarke is a senior biotechnology ... over a,30-year industry career., "It is a ... of our Board,of Directors," said Julie A. Olson, ...
Other Biology Technology:CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line 2CTDC Holds a Ribbon Cutting Ceremony to Showcase First SnO2 Production Line 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 2Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 3Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 4Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues 5Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors 2
(Date:12/15/2009)... a team of Spanish and American researchers found the fossil ... Huelva. Now they have published, for the first time, the ... the death of the young cetacean, possibly a baleen whale ... discovery of the partial fossil remains of a whale from ... Sands sedimentary formation, but it is the first time that ...
(Date:12/15/2009)... future, consumers can look forward to ultra-low powered ... PDAs and mobile phones. This is made possible ... which are critical elements for power optimisation and ... , Analog IC design is the key enabling ... pre-position the nation in advanced analog and mixed ...
(Date:12/15/2009)... laboratory model organism, but there are currently few ... and blood-forming tissues in this species. A ... resources from Cold Spring Harbor Laboratory Press fills ... step-by-step protocols for the preparation, enumeration, and microscopic ... hematopoietic tissues in the mouse. The laboratory ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3New source of classical techniques for blood-based studies in the laboratory mouse 2MedCath Corporation Reports Third Quarter Earnings 53784 1MedCath Corporation Reports Third Quarter Earnings 53784 2MedCath Corporation Reports Third Quarter Earnings 53784 3MedCath Corporation Reports Third Quarter Earnings 53784 4MedCath Corporation Reports Third Quarter Earnings 53784 5MedCath Corporation Reports Third Quarter Earnings 53784 6MedCath Corporation Reports Third Quarter Earnings 53784 7MedCath Corporation Reports Third Quarter Earnings 53784 8MedCath Corporation Reports Third Quarter Earnings 53784 9MedCath Corporation Reports Third Quarter Earnings 53784 10MedCath Corporation Reports Third Quarter Earnings 53784 11MedCath Corporation Reports Third Quarter Earnings 53784 12MedCath Corporation Reports Third Quarter Earnings 53784 13MedCath Corporation Reports Third Quarter Earnings 53784 14MedCath Corporation Reports Third Quarter Earnings 53784 15MedCath Corporation Reports Third Quarter Earnings 53784 16Whats Lurking in Your Kitchen 3F 53781 1Whats Lurking in Your Kitchen 3F 53781 2Whats Lurking in Your Kitchen 3F 53781 3Whats Lurking in Your Kitchen 3F 53781 4NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 1NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 2NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 3NeurogesX Announces New PDUFA Date for Qutenza 28TM 29 New Drug Application 13402 4
... Yale scientists have created nanowire sensors coupled with simple ... to be used for point-of-care (POC) disease detection, according ... The sensors use activation of immune cells by highly ... cells as the detector. When T cells are ...
... may make us all go a little gooey, but it,s ... researchers at The Australian National University. , The study ... ANU suggests that despite fears mothers may have that ... suggest that is true. The findings have been released as ...
... Aware, Inc. (Nasdaq:,AWRE), a leading supplier of broadband technology ... the company,s operating results,for the third quarter of 2008 ... CEO Michael Tzannes and CFO Rick Moberg will host ... by Thomson and can be accessed on the,Investor Relations ...
Other Biology News:Sensitive nanowire disease detectors made by Yale scientists 2Pregnancy not turning minds to mush: Study 2Aware Announces Q3 2008 Earnings Conference Call 2
... The 820-MS features Varians unique ... provides simple, routine removal of troublesome ... more flexible interference-free analysis without the ... quadrupole ion guides, or cells. And, ...
a1-Antitrypsin (human, alpha-1 AT)...
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
... Bio luciferase assay. Mo Bio Laboratories offers the ... you to certify your products ATP-Free with a ... deliver them to your customers in a timely ... 3.5 x 10-12 /l, which will allow you ...
Biology Products: